Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older
NCT05541289 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2022-09-22
Summary
This Expanded Access, Phase 3, open label study is intended to provide access to COVAXIN™ (BBV152) to individuals who are at risk or have predisposing conditions that can lead to complications with the current immunization options against SAR-CoV-2 Virus infection.
Conditions
Interventions
- BIOLOGICAL
-
BBV152
Single Arm; BBV152 (COVAXIN™)
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
NCT04611802 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
NCT05472038 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
NCT04636697 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
NCT04860258 ·Status: TERMINATED ·Phase: PHASE3
-
To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA
NCT06436911 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine
NCT05685953 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
NCT07069309 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose
NCT05567471 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
NCT06065176 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
NCT04895982 ·Status: COMPLETED ·Phase: PHASE2
-
BBV152/BBV154 Heterologus Prime-Boost Study
NCT05639998 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
NCT05463068 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19
NCT04756830 ·Status: UNKNOWN ·Phase: PHASE4
-
COVID-19 Vaccination of Immunodeficient Persons (COVAXID)
NCT04780659 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
NCT05364242 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
NCT05128721 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older
NCT04762680 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
NCT06354998 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
NCT04847102 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
NCT05079152 ·Status: UNKNOWN ·Phase: PHASE4
-
Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.
NCT05710783 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults
NCT04591184 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
NCT05506969 ·Status: COMPLETED ·Phase: PHASE2